Niemann-Pick Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Niemann-Pick disease (NPD) is a lysosomal storage disorder caused by acid sphingomyelinase deficiency (ASMD), which is characterized by the impairment of the enzyme responsible for the hydrolysis of sphingomyelin (SM) to ceramide and phosphocholine. The accumulation of SM and its precursor lipids within lysosomes, primarily in macrophages, leads to lipid-laden macrophages that deposit in various organs, including the liver, spleen, lungs, and brain. This leads to clinical symptoms such as hepatosplenomegaly, cytopenias, lung disease, and neurologic symptoms. NPD is traditionally classified into four subtypes: type A, B, C, and E. The genetic basis of NPD is inherited in an autosomal recessive pattern, meaning that both copies of the gene must have mutations for the disease to manifest. NPD types A and B are caused by missense mutations in the sphingomyelin phosphodiesterase 1 (SMPD1) gene, of which over 180 have been identified. NPD type C is caused by mutations in the NPC1 (located on chromosome 18) and NPC2 (located on chromosome 14) genes, which lead to abnormal or defective protein formation and impaired lipid transport out of cells, resulting in their accumulation within the cells. Differential diagnoses for NPD include other lysosomal storage disorders such as Gaucher disease, Tay-Sachs disease, Metachromatic leukodystrophy, and other diseases that affect the liver and brain. NPD is a progressive disorder; over time, complications can develop, such as fulminant hepatic failure, respiratory insufficiency, progressive neurodegeneration, severe thrombocytopenia, coronary artery and valvular heart disease, and deformation of bones.
·
Niemann-Pick disease type A and B affects 1 in
250,000 individuals. NPD type C affects 1 in 150,000 individuals.
Thelansis’s “Niemann-Pick Disease
Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Niemann-Pick
Disease treatment modalities options for eight major markets (USA, Germany,
France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Niemann-Pick Disease across 8 MM market from the centre of Excellence/
Public/ Private hospitals participated in the study. Insights around current
treatment landscape, epidemiology, clinical characteristics, future treatment
paradigm, and Unmet needs.
Niemann-Pick Disease Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment